Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP inhibition in treatment of pancreatic cancer.
Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M. Hammel P, et al. Among authors: bouattour m. Expert Rev Anticancer Ther. 2020 Nov;20(11):939-945. doi: 10.1080/14737140.2020.1820330. Epub 2020 Sep 16. Expert Rev Anticancer Ther. 2020. PMID: 32936674 Review.
Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005.
Wisniewski M, Placide PA, Granier S, Al Shatti Y, Al Qalaf S, Bouattour M, Lamuraglia M, Hammel P. Wisniewski M, et al. Among authors: bouattour m. Hepatobiliary Surg Nutr. 2018 Oct;7(5):399-402. doi: 10.21037/hbsn.2018.08.03. Hepatobiliary Surg Nutr. 2018. PMID: 30498718 Free PMC article. No abstract available.
Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group. Baroudjian B, et al. Among authors: bouattour m. Expert Rev Anticancer Ther. 2019 Mar;19(3):209-222. doi: 10.1080/14737140.2019.1562342. Epub 2019 Jan 9. Expert Rev Anticancer Ther. 2019. PMID: 30572735 Review.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: bouattour m. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
[Targeted therapies in colorectal cancer].
Sablin MP, Dreyer C, Colichi C, Bouattour M, Faivre S. Sablin MP, et al. Among authors: bouattour m. Rev Prat. 2010 Oct 20;60(8):1094-9. Rev Prat. 2010. PMID: 21197741 French.
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E. Faivre S, et al. Among authors: bouattour m. Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531821 Clinical Trial.
89 results